Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial

被引:44
|
作者
Koz, Ozlem Gurbuz
Ozsoy, Arzu
Yarangumeli, Alper
Kose, S. Kenan
Kural, Gulcan
机构
[1] Ankara Numune Training & Res Hosp, Ankara, Turkey
[2] Ankara Univ, Sch Med, Dept Biostat, TR-06100 Ankara, Turkey
来源
ACTA OPHTHALMOLOGICA SCANDINAVICA | 2007年 / 85卷 / 08期
关键词
colour Doppler ultrasound; ocular circulation; prostaglandin analogues;
D O I
10.1111/j.1600-0420.2007.00960.x
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To study the effect of three prostaglandin F2-alpha (PG) analogues on retrobulbar blood flow velocity in previously untreated patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), using colour Doppler ultrasound. Methods: Sixty newly diagnosed patients with POAG or OHT were randomly assigned to travoprost 0.004% (n = 12 with POAG, n = 8 with OHT), latanoprost 0.005% (n = 11 with POAG, n = 9 with OHT) and bimatoprost 0.03% (n = 13 with POAG, n = 7 with OHT) treatment groups in a double-masked fashion. At baseline examination, blood pressure, heart rate and intraocular pressure (IOP) were recorded. Peak-systolic and end-diastolic velocities were measured in the ophthalmic (OA), central retinal (CRA) and temporal short posterior ciliary arteries (PCA). The resistive index (RI) and ocular perfusion pressure (OPP) were determined for each treatment group. After a treatment period of 6-months, all procedures were repeated. Results: There were no significant differences in age (53 +/- 14 years in the travoprost group, 51 +/- 14 years in the latanoprost group, 53 +/- 11 years in the bimatoprost group), gender (11 men, nine women; 11 men, nine women; 13 men, seven women, by group, respectively), or clinical diagnosis (POAG or OHT) among treatment groups (p > 0.05). A significant decrease in IOP (baseline: 26.4 +/- 3.3 mmHg, 26.8 +/- 1.3 mmHg, 25.8 +/- 1.8 mmHg, respectively; month 6: 20.9 +/- 1.9 mmHg, 20.8 +/- 2.4 mmHg, 18.3 +/- 1.2 mmHg, respectively; p < 0.0001) and an increase in OPP (baseline: 33.7 +/- 3.8 mmHg, 33.5 +/- 3.2 mmHg, 33.9 +/- 2.6 mmHg, respectively; month 6: 40.2 +/- 3.5 mmHg, 39.9 +/- 3.1 mmHg, 41.7 +/- 2.6 mmHg, respectively; p < 0.0001) were verified in all three groups during the study period. Mean baseline RI values for the CRA in the travoprost group and the OA in the latanoprost group were both 0.7 +/- 0.1 mmHg and both values were statistically significantly lower at 6 months (0.6 +/- 0.1 mmHg in both groups; p = 0.002, p < 0.0001, respectively). In the bimatoprost group there was no statistically significant difference in haemodynamic parameters over the study period (p > 0.05). Conclusions: Our results suggest that the three PG analogues significantly reduce IOP and increase OPP in patients with POAG or OHT. Topical travoprost and latanoprost significantly reduce the RI of the CRA and OA, respectively. We were unable to determine any effect of topical bimatoprost on ocular haemodynamics.
引用
收藏
页码:838 / 843
页数:6
相关论文
共 50 条
  • [41] A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension
    Walt, JG
    Lee, JT
    SURVEY OF OPHTHALMOLOGY, 2004, 49 : S36 - S44
  • [42] Comparison of clinically relevant response rates to bimatoprost and latanoprost in patients with ocular hypertension or glaucoma
    Choplin, NT
    Dirks, MS
    Tepedino, M
    Batoosingh, A
    Bernstein, P
    Whitcup, SM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U377 - U377
  • [44] In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line
    Brasnu, Emmanuelle
    Brignole-Bauclouin, Francoise
    Riancho, Luisa
    Guenoun, Jean-Marc
    Warnet, Jean-Michel
    Baudouin, Christophe
    CURRENT EYE RESEARCH, 2008, 33 (04) : 303 - 312
  • [45] Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study
    Kammer, J. A.
    Katzman, B.
    Ackerman, S. L.
    Hollander, D. A.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2010, 94 (01) : 74 - 79
  • [46] The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol
    Inan, UB
    Ermis, SS
    Orman, A
    Onrat, E
    Yucel, A
    Ozturk, F
    Asagidag, A
    Celik, A
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2004, 20 (04) : 293 - 310
  • [47] Comparison of the Diurnal Intraocular Pressure-Lowering Efficacy of Bimatoprost 0.03%, Latanoprost 0.005% and Travoprost 0.004% in Patients with Glaucoma
    Ferreras, A.
    Pajarin, A. B.
    Pablo, L. E.
    Larrosa, J. M.
    Polo, V.
    PROCEEDINGS OF THE 7TH INTERNATIONAL SYMPOSIUM ON OCULAR PHARMACOLOGY AND THERAPEUTICS, 2008, : 119 - +
  • [48] Interaction of Ocular Hypotensive Agents (PGF2α Analogs-Bimatoprost, Latanoprost, and Travoprost) With MDR Efflux Pumps on the Rabbit Cornea
    Hariharan, Sudharshan
    Minocha, Mukul
    Mishra, Gyan P.
    Pal, Dhananjay
    Krishna, Rohit
    Mitra, Ashim K.
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2009, 25 (06) : 487 - 497
  • [49] A 6-MONTH BURDEN ON RIGHT TO TRIAL
    JOST, K
    ABA JOURNAL, 1993, 79 : 34 - 34
  • [50] Reporting of 6-month vs 12-month data in a clinical trial of celecoxib
    Hrachovec, JB
    Mora, M
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (19): : 2398 - 2398